What are desmoplastic infantile ganglioglioma and astrocytoma?
Desmoplastic infantile ganglioglioma (DIG) and desmoplastic infantile astrocytoma (DIA) are rare brain tumours of babies and very young children. They are usually very large when found, with a big fluid-filled cyst and a solid part that sits on the surface of the brain and sticks to its outer covering, the dura.
Despite their size and dramatic appearance on scans, these tumours are usually slow-growing and low-grade. The World Health Organization (WHO) classifies them together as a single tumour type, CNS WHO grade 1, the lowest grade (Wang et al., 2021). Most children do well after surgery.
The word desmoplastic means that the tumour contains a lot of tough, scar-like connective tissue. Ganglioglioma means the tumour contains both nerve cells (ganglion cells) and glial support cells. In astrocytoma, only glial cells (astrocytes) are seen. DIG is more common than DIA.
How it differs from ganglioglioma
Ordinary ganglioglioma, described on our page on ganglioglioma, is also a low-grade tumour made of nerve and glial cells. However, it usually affects older children and young adults and typically causes epilepsy.
| Feature | Ganglioglioma | DIG/DIA |
|---|---|---|
| Typical age | Older children, teenagers and young adults | Babies, usually under two |
| Size at diagnosis | Usually small | Often very large |
| Cyst | Sometimes | Usually a large cyst |
| Dura | Usually not attached | Attached to the brain covering |
| First symptom | Seizures | Rapidly growing head, bulging soft spot |
| Scar-like tissue | Limited | Abundant |
| Grade | CNS WHO grade 1 | CNS WHO grade 1 |
1. Key facts at a glance
| Feature | Details |
|---|---|
| Type of tumour | Low-grade glioneuronal or glial brain tumour |
| Grade | CNS WHO grade 1 |
| How common | Very rare; a few hundred cases reported worldwide |
| Typical age | Babies; median around 7 months in a pooled analysis |
| Sex | Slightly more common in boys |
| Location | Surface of the cerebral hemispheres, often frontal and parietal lobes |
| Main treatment | Surgery |
| Other treatments | Observation, chemotherapy or targeted drugs for regrowth |
| Outlook | Usually very good |
2. Types
| Type | Cells present | Notes |
|---|---|---|
| DIG | Astrocytes plus nerve (ganglion) cells | About two-thirds of cases |
| DIA | Astrocytes only | About a quarter of cases |
| Non-infantile desmoplastic tumours | Same features in older children or adults | Rare |
In an individual patient analysis of 188 published cases, about 68% were DIG and 25% were DIA. DIA was more often found in deep locations and was more often associated with spread along the brain coverings (Wang et al., 2021).
Molecular groups
Researchers now use DNA methylation profiling to classify brain tumours. DIG/DIA has its own methylation group. Gene changes in the MAPK pathway, especially BRAF mutations, are found in a subset, roughly one in three cases (Lampros et al., 2025).
3. Causes and risk factors
The cause is not known. These tumours appear to begin during brain development before or shortly after birth.
| Factor | Notes |
|---|---|
| Age | Almost all cases occur in the first two years of life |
| Sex | Slight male predominance |
| BRAF and other MAPK gene changes | Present in the tumour in some children |
| Inherited conditions | None known |
| Pregnancy factors | No known link with anything the parents did |
Parents often ask whether something during pregnancy caused the tumour. There is no evidence that diet, medicines, infections or other exposures during pregnancy play a role.
4. How does it look
On scans
| Scan | Typical findings |
|---|---|
| Cranial ultrasound | Through the soft spot in babies; may first show a large mass or cyst |
| CT | Very large cyst with a solid part near the surface; may show pressure on the brain |
| MRI | Large cyst with a solid nodule that enhances strongly with contrast and is attached to the dura |
| Spine MRI | Looks for spread along the spinal coverings |
Typical MRI features include a large, mixed solid and cystic mass with a solid part that lights up brightly with contrast (Bianchi et al., 2016). In an Italian series, tumours averaged more than 200 cm3 in volume, which is very large for a baby’s head (Imperato et al., 2021).
Under the microscope
| Feature | Description |
|---|---|
| Desmoplastic stroma | Dense connective tissue rich in reticulin fibres |
| Astrocytes | Elongated glial cells, positive for GFAP |
| Ganglion cells | Present in DIG; positive for neuronal markers such as synaptophysin |
| Primitive cells | Small immature cells may be present and can look worrying |
| Ki-67 index | Usually low |
The small primitive cells can resemble a high-grade tumour. Pathologists know this pattern and do not take it as a sign of malignancy on its own (Bianchi et al., 2016).
5. Symptoms
Babies’ skull bones are not yet fused, so the head can expand as a tumour grows. This often allows the tumour to become very large before symptoms appear.
Common symptoms
- Rapid growth of the head (increasing head circumference)
- A tense or bulging soft spot (fontanelle)
- Vomiting and irritability
- Sleepiness or reduced feeding
- Seizures
Less common symptoms
| Symptom | Possible cause |
|---|---|
| Eyes looking downwards (“setting sun” sign) | Raised pressure in the head |
| Weakness of one side of the body | Pressure on movement areas |
| Delayed development | Long-standing pressure or seizures |
| Prominent scalp veins | Raised pressure |
A review of 222 patients found that hydrocephalus, a build-up of fluid in the head, was the most common first sign in babies, while seizures were more common in older children (Lampros et al., 2025).
When to seek medical advice
Take your baby to a doctor urgently if the head is growing quickly, the soft spot is bulging, or your baby is vomiting repeatedly, unusually sleepy or has a seizure.
6. Diagnosis
| Step | What is done |
|---|---|
| Examination | Head size measurement, fontanelle check, neurological assessment |
| Ultrasound | Quick first test in young babies |
| MRI of the brain and spine | Main imaging test, often under sedation or general anaesthetic |
| Blood tests | Blood count and clotting before surgery |
| Surgery | Provides tissue for diagnosis and removes the tumour |
| Molecular testing | BRAF and methylation profiling |
Why surgery comes first
In most brain tumours, doctors try to confirm the diagnosis with a biopsy before planning treatment. With DIG/DIA, the tumour is usually so large and causes so much pressure that an operation is needed straight away. The surgery both relieves the pressure and provides tissue for diagnosis.
7. Treatment
Treatment takes place at a children’s neurosurgical centre with a paediatric neuro-oncology team.
Surgery
| Aspect | Details |
|---|---|
| Aim | Remove as much tumour as safely possible |
| Cyst drainage | The large cyst is drained during surgery |
| Challenges | Very large, vascular tumours in small babies with little blood volume |
| Staged operations | Sometimes needed for very large tumours |
| Hydrocephalus treatment | A shunt may be needed in some children |
Complete removal is the goal, but it is often difficult. The literature shows total removal in roughly a third to just over half of children (Bianchi et al., 2016; Lampros et al., 2025). Blood loss during surgery is a real risk in tiny babies, and one baby in the Italian series died from it soon after the operation (Imperato et al., 2021).
After partial removal
| Situation | Usual approach |
|---|---|
| Stable remaining tumour | Regular MRI monitoring |
| Growth of remaining tumour | Repeat surgery is often the first option |
| Tumour that cannot be removed | Chemotherapy |
| BRAF-mutated tumour | BRAF and MEK inhibitors may be considered |
Remaining tumour often stays stable or even shrinks. In the Italian series, more than half the children needed more than one operation, yet most were alive and well at last follow-up (Imperato et al., 2021).
Chemotherapy and targeted drugs
| Treatment | Notes |
|---|---|
| Carboplatin and vincristine | Common first choice when drug treatment is needed |
| Other low-grade glioma regimens | Used for progression |
| BRAF and MEK inhibitors | Options for tumours with BRAF changes |
Radiotherapy
Radiotherapy is avoided in young children because of serious long-term effects on the developing brain. Experts consider it to have no routine role in DIG/DIA (Imperato et al., 2021).
Side effects
| Treatment | Possible side effects |
|---|---|
| Surgery | Bleeding, infection, seizures, weakness, need for a shunt |
| Shunt | Blockage or infection needing further surgery |
| Carboplatin and vincristine | Low blood counts, infection, allergic reactions, constipation, nerve effects |
| BRAF and MEK inhibitors | Skin rash, fever, tiredness, eye or heart effects |
8. Outlook (prognosis)
The outlook is usually very good. In a review of 222 patients, recurrence occurred in about 6% and spread in about 2%, and long-term survival was high (Lampros et al., 2025).
| Factor | Effect |
|---|---|
| Complete removal | Linked to better survival in a pooled analysis |
| Spread along the brain coverings at diagnosis | Linked to higher mortality |
| Deep location | Linked to more regrowth |
| High Ki-67 (over 20%) | Linked to higher recurrence risk |
| Multifocal tumours | Linked to recurrence or spread |
These factors come from Wang et al. (2021) and Lampros et al. (2025). Tumours in the hypothalamus or other midline areas tend to be harder to treat (Bianchi et al., 2016).
Development and learning
Many children develop normally. Some may have epilepsy, weakness or learning difficulties, depending on the tumour’s location, the pressure it caused and the treatment needed. Early support helps them reach their potential.
9. Follow-up
| Period | Typical checks |
|---|---|
| First year after surgery | MRI every 3-4 months |
| Years 2-5 | MRI every 6-12 months |
| Later | Less frequent MRI as advised |
| Development | Regular reviews of growth, development and learning |
| Seizures | Neurology follow-up if needed |
10. Living with DIG/DIA
- Keep all MRI and clinic appointments
- Know the signs of a blocked shunt: vomiting, sleepiness, headache or bulging fontanelle
- Give anti-seizure medicines as prescribed
- Use early intervention services such as physiotherapy, occupational therapy and speech therapy
- Tell nursery or school staff about your child’s condition
- Look after yourselves as parents, and accept help from family and support services
After brain surgery
| Period | What to expect |
|---|---|
| First days | Care in a high-dependency or intensive care unit; close monitoring |
| First 1-2 weeks | Return to the ward, feeding and wound checks; first MRI to see how much tumour remains |
| Weeks to months | Recovery of strength; therapy for any weakness |
| Pathology results | Usually available within one to two weeks, with molecular results later |
Support for families
Hearing that your baby has a brain tumour is overwhelming. Children’s cancer centres offer specialist nurses, psychologists, social workers and play specialists. Charities for children with brain tumours provide information, financial help and the chance to meet other families.
11. Frequently asked questions
| Question | Answer |
|---|---|
| Is it cancer? | It is a tumour, but it is low-grade and usually behaves benignly |
| Why is it so big? | A baby’s skull can expand, so the tumour grows large before symptoms appear |
| Will my baby need chemotherapy? | Only if the tumour regrows and cannot be removed |
| Will radiotherapy be used? | Usually not, to protect the developing brain |
| Can it come back? | Sometimes, especially if not fully removed, so scans continue |
| Did we cause it? | No; nothing parents did is known to cause it |
| How long will follow-up last? | Usually many years, with scans becoming less frequent over time |
| Can my baby have routine vaccinations? | Usually yes, though timing may change during chemotherapy; ask your team |
| Will my child develop normally? | Many do; some need extra support |
12. Questions to ask your care team
- Is the tumour a DIG or DIA?
- Was it completely removed?
- Does it have a BRAF or other gene change?
- Will my child need more surgery or chemotherapy?
- Does my child need a shunt?
- How often will MRI scans be done?
- What developmental support is available?
Resources
- Bianchi, F. et al. (2016) ‘Supratentorial tumors typical of the infantile age: desmoplastic infantile ganglioglioma (DIG) and astrocytoma (DIA). A review’, Child’s Nervous System, 32(10), pp. 1833-1838.
- Imperato, A. et al. (2021) ‘Desmoplastic infantile astrocytoma and ganglioglioma: a series of 12 patients treated at a single institution’, Child’s Nervous System, 37(7), pp. 2187-2195.
- Lampros, M. et al. (2025) ‘Desmoplastic infantile ganglioglioma and astrocytoma: a narrative review of the literature’, Child’s Nervous System, 41(1), 324.
- Wang, S. et al. (2021) ‘Predictors of mortality and tumor recurrence in desmoplastic infantile ganglioglioma and astrocytoma: an individual participant data meta-analysis (IPDMA)’, Journal of Neuro-Oncology, 155(2), pp. 155-163.
- National Cancer Institute (2026) Childhood Astrocytomas and Other Gliomas Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/brain/hp/child-astrocytoma-glioma-treatment-pdq (Accessed: October 2026).
Prepared by the editorial team, October 2026.